Mizagliflozin manufacturers
- Mizagliflozin
-
- $61.00 / 1mg
-
2026-03-06
- CAS:666843-10-3
- Min. Order:
- Purity: 99.60%
- Supply Ability: 10g
|
| | Mizagliflozin Basic information |
| Product Name: | Mizagliflozin | | Synonyms: | Mizagliflozin;DSP-3235 free base;GSK-1614235 free base;KGA-3235 free base;Propanamide, 3-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]propyl]amino]-2,2-dimethyl-;GSK1614235,Chronic,KGA 3235,DSP-3235,selective,Sodium-dependent glucose cotransporters,KGA-3235,constipation,Mizagliflozin,antidiabetic,disorder,SGLT,gastrointestinal,DSP 3235,inhibit,GSK 1614235,Inhibitor,KGA3235,GSK-1614235,DSP3235;Mizagliflozin (KWA 0711);GSK 1614235 | | CAS: | 666843-10-3 | | MF: | C28H44N4O8 | | MW: | 564.68 | | EINECS: | | | Product Categories: | | | Mol File: | 666843-10-3.mol |  |
| | Mizagliflozin Chemical Properties |
| Boiling point | 837.0±65.0 °C(Predicted) | | density | 1.274±0.06 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | Methanol: 250 mg/mL (442.74 mM); DMSO: 100 mg/mL (177.09 mM) | | form | Solid | | pka | 12.65±0.70(Predicted) | | color | Off-white to light yellow |
| | Mizagliflozin Usage And Synthesis |
| Uses | Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation[1]. | | in vivo | Mizagliflozin (DSP-3235 free base) (3-30 mg/kg; oral) exerts a laxative effect[1].
Mizagliflozin administrated intravenously (0.3 mg/kg) and orally (3 mg/kg) declined with a short half-life (0.23 and 1.14 h, respectively)[2] | Animal Model: | Male Wistar rats (rat model of low-fiber-diet-induced constipation)[1] | | Dosage: | 3, 10, 30 mg/kg | | Administration: | Oral | | Result: | Increased fecal wet weight in a rat model of low-fiber-diet-induced constipation. |
| | IC 50 | SGLT1 | | References | [1] Inoue T, et al. Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. Eur J Pharmacol. 2017 Jul 5;806:25-31. DOI:10.1016/j.ejphar.2017.04.010
[2] Ohno H, et al. Absorption, disposition, metabolism and excretion of [14C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats. Xenobiotica. 2019 Apr;49(4):463-473. DOI:10.1080/00498254.2018.1449269 |
| | Mizagliflozin Preparation Products And Raw materials |
|